MRUS - Merus N.V
IEX Last Trade
50.99
0.510 1.000%
Share volume: 378,905
Last Updated: Fri 30 Aug 2024 09:59:47 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$50.48
0.51
1.01%
Fundamental analysis
26%
Profitability
25%
Dept financing
14%
Liquidity
50%
Performance
25%
Performance
5 Days
-4.85%
1 Month
-4.46%
3 Months
-11.01%
6 Months
4.70%
1 Year
138.16%
2 Year
125.22%
Key data
Stock price
$50.99
DAY RANGE
N/A - N/A
52 WEEK RANGE
$19.81 - $61.61
52 WEEK CHANGE
$1.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Sven Lundberg
Region: US
Website: https://www.merus.nl/
Employees: 202
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.merus.nl/
Employees: 202
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Recent news